Hexarhinal (Xylometazoline Hydrochloride)

Hexarhinal is indicated for temporary relief of nasal blockage associated with several common upper‑respiratory conditions.

• Nasal congestion caused by the common cold, providing short‑term airway opening.
• Congestion related to acute sinusitis, helping reduce mucosal swelling.
• Nasal obstruction due to allergic rhinitis, easing breathing during allergen exposure.
• Relief of swelling in the nasal passages during seasonal allergies.
• Symptomatic relief of nasal blockage accompanying upper‑respiratory tract infections such as flu.
• Temporary reduction of nasal stuffiness after exposure to irritants like smoke or pollution.

• Xylometazoline Hydrochloride acts as a selective alpha‑adrenergic agonist on the α1‑ and α2‑receptors of the nasal mucosal blood vessels. Stimulation of these receptors induces vasoconstriction, which decreases blood flow to the nasal epithelium, reduces edema, and opens the airway. The localized effect limits systemic absorption, providing rapid decongestion without significant systemic adrenergic activity. The vasoconstrictive response typically begins within minutes and can last for several hours, supporting short‑term symptom control.

Like most nasal decongestants, Hexarhinal may cause local or systemic adverse reactions, most of which are mild and transient.

Common

• Burning or stinging sensation in the nasal passages, usually resolving within minutes.
• Dryness or irritation of the nasal mucosa that may cause mild discomfort.
• Sneezing episodes occurring shortly after administration of the spray.
• Unpleasant bitter taste or throat irritation following nasal use.

Serious

• Rebound nasal congestion (rhinitis medicamentosa) after use for more than three consecutive days.
• Ulceration or bleeding of the nasal mucosa indicating local tissue irritation.
• Increase in blood pressure, especially in patients with pre‑existing hypertension.
• Severe hypersensitivity reactions such as rash, facial swelling, or difficulty breathing.

Before using Hexarhinal, consider the following precautions to minimize risks and ensure appropriate use.

• Limit use to no more than three consecutive days to avoid rebound congestion.
• Do not use if you have known hypersensitivity to xylometazoline or any component of the product.
• Consult a healthcare professional before use if you have hypertension, heart disease, diabetes, or thyroid disorders.
• Use caution in pregnant or breastfeeding women; safety has not been established.
• Avoid use in children younger than the age stated on the label.
• Do not share the spray to prevent cross‑contamination.

Hexarhinal can interact with certain medications or substances; consider the following guidance.

Avoid

• Concurrent use with monoamine oxidase inhibitors (MAOIs) or other potent vasoconstrictors, which may increase systemic adrenergic effects.
• Combining with other nasal decongestant sprays or drops, raising the risk of excessive vasoconstriction and rebound congestion.

Use with caution

• Use cautiously with antihypertensive drugs, as systemic absorption may modestly affect blood pressure.
• Caution when using with tricyclic antidepressants or sympathomimetic agents, which could potentiate cardiovascular stimulation.
• Monitor for interactions in patients taking thyroid hormone preparations, as adrenergic activity may alter metabolic response.